565 related articles for article (PubMed ID: 27521339)
21. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.
Coll RC; Hill JR; Day CJ; Zamoshnikova A; Boucher D; Massey NL; Chitty JL; Fraser JA; Jennings MP; Robertson AAB; Schroder K
Nat Chem Biol; 2019 Jun; 15(6):556-559. PubMed ID: 31086327
[TBL] [Abstract][Full Text] [Related]
22. Targeting the NLRP3 Inflammasome in Severe COVID-19.
Freeman TL; Swartz TH
Front Immunol; 2020; 11():1518. PubMed ID: 32655582
[TBL] [Abstract][Full Text] [Related]
23. α1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid β
Ebrahimi T; Rust M; Kaiser SN; Slowik A; Beyer C; Koczulla AR; Schulz JB; Habib P; Bach JP
J Neuroinflammation; 2018 Sep; 15(1):282. PubMed ID: 30261895
[TBL] [Abstract][Full Text] [Related]
24. NLRP3 inflammasome inhibition attenuates subacute neurotoxicity induced by acrylamide in vitro and in vivo.
Sui X; Yang J; Zhang G; Yuan X; Li W; Long J; Luo Y; Li Y; Wang Y
Toxicology; 2020 Feb; 432():152392. PubMed ID: 32014472
[TBL] [Abstract][Full Text] [Related]
25. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
Zhang W; Ba G; Tang R; Li M; Lin H
Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
[TBL] [Abstract][Full Text] [Related]
26. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease.
Huang S; Chen Z; Fan B; Chen Y; Zhou L; Jiang B; Long H; Zhong W; Li X; Li Y
J Neuroimmunol; 2021 May; 354():577543. PubMed ID: 33714750
[TBL] [Abstract][Full Text] [Related]
27. Role of the NLRP3 inflammasome in a model of acute burn-induced pain.
Deuis JR; Yin K; Cooper MA; Schroder K; Vetter I
Burns; 2017 Mar; 43(2):304-309. PubMed ID: 28040362
[TBL] [Abstract][Full Text] [Related]
28. Second-Generation Antidiabetic Sulfonylureas Inhibit Candida albicans and Candidalysin-Mediated Activation of the NLRP3 Inflammasome.
Lowes DJ; Hevener KE; Peters BM
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712208
[TBL] [Abstract][Full Text] [Related]
29. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
[TBL] [Abstract][Full Text] [Related]
30. Extent of Ischemic Brain Injury After Thrombotic Stroke Is Independent of the NLRP3 (NACHT, LRR and PYD Domains-Containing Protein 3) Inflammasome.
Lemarchand E; Barrington J; Chenery A; Haley M; Coutts G; Allen JE; Allan SM; Brough D
Stroke; 2019 May; 50(5):1232-1239. PubMed ID: 31009361
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological inhibition of the NLRP3 inflammasome as a potential target for cancer-induced bone pain.
Chen SP; Zhou YQ; Wang XM; Sun J; Cao F; HaiSam S; Ye DW; Tian YK
Pharmacol Res; 2019 Sep; 147():104339. PubMed ID: 31276771
[TBL] [Abstract][Full Text] [Related]
32. Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model.
He W; Long T; Pan Q; Zhang S; Zhang Y; Zhang D; Qin G; Chen L; Zhou J
J Neuroinflammation; 2019 Apr; 16(1):78. PubMed ID: 30971286
[TBL] [Abstract][Full Text] [Related]
33. NLRP3 regulates alveolar bone loss in ligature-induced periodontitis by promoting osteoclastic differentiation.
Chen Y; Yang Q; Lv C; Chen Y; Zhao W; Li W; Chen H; Wang H; Sun W; Yuan H
Cell Prolif; 2021 Feb; 54(2):e12973. PubMed ID: 33382502
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
[TBL] [Abstract][Full Text] [Related]
35. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.
van Hout GP; Bosch L; Ellenbroek GH; de Haan JJ; van Solinge WW; Cooper MA; Arslan F; de Jager SC; Robertson AA; Pasterkamp G; Hoefer IE
Eur Heart J; 2017 Mar; 38(11):828-836. PubMed ID: 27432019
[TBL] [Abstract][Full Text] [Related]
36. The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice.
Gao RF; Li X; Xiang HY; Yang H; Lv CY; Sun XL; Chen HZ; Gao Y; Yang JS; Luo W; Yang YQ; Tang YH
Int Immunopharmacol; 2021 Jan; 90():107133. PubMed ID: 33168408
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
[TBL] [Abstract][Full Text] [Related]
38. MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes.
Bakhshi S; Shamsi S
Int Immunopharmacol; 2022 May; 106():108595. PubMed ID: 35124417
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke.
Ismael S; Zhao L; Nasoohi S; Ishrat T
Sci Rep; 2018 Apr; 8(1):5971. PubMed ID: 29654318
[TBL] [Abstract][Full Text] [Related]
40. The selective Nlrp3 inflammasome inhibitor Mcc950 attenuates lung ischemia-reperfusion injury.
Xu KY; Wu CY; Tong S; Xiong P; Wang SH
Biochem Biophys Res Commun; 2018 Sep; 503(4):3031-3037. PubMed ID: 30146255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
